Glenmark Generics Inc, USA, a subsidiary of Glenmark Pharmaceuticals has been granted final abbreviated new drug approvals (ANDA’s) from the United States Food and Drug Administration (USFDA) for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg. The pharma major will commence distribution of the product immediately.
Zolmitriptan Tablets and Zolmitriptan ODT are Glenmark’s generic versions of Zomig and Zomig ZMT by AstraZeneca, indicated for the acute treatment of migraine headaches in adults. According to IMS Health for the 12 month period ending December 2012, the products garnered annual sales of $176 million.
Glenmark’s current •portfolio consists of 85 products authorized for distribution in the US marketplace and 50 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: